Chordia Therapeutics Inc. (TYO:190A)

Japan flag Japan · Delayed Price · Currency is JPY
225.00
+1.00 (0.45%)
May 29, 2025, 1:45 PM JST
-11.76%
Market Cap 15.45B
Revenue (ttm) n/a
Net Income (ttm) -2.00B
Shares Out 68.99M
EPS (ttm) -30.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 258,100
Average Volume 518,630
Open 224.00
Previous Close 224.00
Day's Range 223.00 - 227.00
52-Week Range 142.00 - 930.00
Beta n/a
RSI 41.98
Earnings Date Jul 14, 2025

About Chordia Therapeutics

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. The company was incorporated in 2017 and is based in Fujisawa, Japan. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2017
Employees 23
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 190A
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.